Page last updated: 2024-09-04

moxifloxacin and Endotoxin Shock

moxifloxacin has been researched along with Endotoxin Shock in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bloos, F; Bode-Böger, SM; Brunkhorst, FM; Burkhardt, O; Greer, MW; Martens-Lobenhoffer, J; Pletz, MW; Stass, H; Welte, T	1
Dannecker, G; Hess, S; Hospach, T; Magdorf, K; Nossal, R; Uhlemann, F	1
Bach, F; Bloos, F; Bogatsch, H; Brunkhorst, FM; Büchler, MW; Engel, C; Fritz, H; Gründling, M; Jaschinski, U; John, S; Kiehntopf, M; Kollef, MH; Kuhnt, E; Loeffler, M; Ludewig, K; Marx, G; Meier-Hellmann, A; Moerer, O; Nierhaus, A; Oppert, M; Putensen, C; Ragaller, M; Reill, L; Reinhart, K; Riessen, R; Seibel, A; Spies, C; Welte, T; Weyland, A	1

Trials

2 trial(s) available for moxifloxacin and Endotoxin Shock

Article	Year
Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive care medicine, 2010, Volume: 36, Issue:6 Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Germany; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Severity of Illness Index; Shock, Septic; Young Adult	2010
Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA, 2012, Jun-13, Volume: 307, Issue:22 Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Meropenem; Middle Aged; Moxifloxacin; Multiple Organ Failure; Quinolines; Sepsis; Shock, Septic; Survival Analysis; Thienamycins; Treatment Outcome	2012

Article

Year

Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock.

Intensive care medicine, 2010, Volume: 36, Issue:6

Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Germany; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Severity of Illness Index; Shock, Septic; Young Adult

2010

Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.

JAMA, 2012, Jun-13, Volume: 307, Issue:22

Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Meropenem; Middle Aged; Moxifloxacin; Multiple Organ Failure; Quinolines; Sepsis; Shock, Septic; Survival Analysis; Thienamycins; Treatment Outcome

2012

Other Studies

1 other study(ies) available for moxifloxacin and Endotoxin Shock

Article	Year
Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent. European journal of pediatrics, 2011, Volume: 170, Issue:10 Topics: Acquired Hyperostosis Syndrome; Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Dyspnea; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Immunosuppressive Agents; Moxifloxacin; Quinolines; Severity of Illness Index; Shock, Septic; Treatment Outcome; Tuberculosis, Miliary; Tumor Necrosis Factor-alpha	2011

Article

Year

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.

European journal of pediatrics, 2011, Volume: 170, Issue:10

Topics: Acquired Hyperostosis Syndrome; Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Dyspnea; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Immunosuppressive Agents; Moxifloxacin; Quinolines; Severity of Illness Index; Shock, Septic; Treatment Outcome; Tuberculosis, Miliary; Tumor Necrosis Factor-alpha

2011